Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Postoperative Non-pCR NSCLC
NCT06352008Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jul 2024; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06352008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352008.